New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 9, 2012
08:41 EDTAVNR, IPXLAvanir sues Impax over planned Nuedexta generic, Bloomberg reports
Avanir Pharmaceuticals (AVNR) is suing Impax Laboratories (IPXL) for allegedly infringing a new patent for the drug Nuedexta and planning to market a generic version of the drug before the patent expires in 2023, reported Bloomberg, citing a complaint filed in a federal court in Delaware. Reference Link
News For AVNR;IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
10:09 EDTIPXLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:58 EDTIPXLImpax initiated with an Outperform at JMP Securities
Subscribe for More Information
October 14, 2014
07:11 EDTAVNRAvanir AVP-923 data looks better than expected, says Piper Jaffray
Piper Jaffray says the Phase II data Avanir presented for AVP-923 in Alzheimer's agitation at the American Neurological Association Monday was better than expected and could open the door for a billion dollar opportunity. It reiterates an Overweight rating on the stock with a $21 price target.
October 13, 2014
16:32 EDTAVNRAvanir Phase 2 AVP-923 study shows improvement in agitation on primary endpoint
Subscribe for More Information
07:33 EDTAVNRAmerican Neurological Association to hold annual meeting
ANA 2014: 139th Annual Meeting is being held in Baltimore on October 12-14.
October 10, 2014
10:01 EDTIPXLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:35 EDTIPXLImpax upgraded to Buy from Hold at WallachBeth
Subscribe for More Information
06:58 EDTIPXLImpax upgraded to Buy from Hold at Needham
Subscribe for More Information
October 9, 2014
07:21 EDTIPXLImpax to host conference call
Subscribe for More Information
06:13 EDTIPXLImpax to acquire Tower Holdings, Lineage Therapeutics for $700M cash
Subscribe for More Information
06:11 EDTIPXLImpax to acquire Tower Holdings, Lineage Therapeutics for $700M cash
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use